Biocelect Pty Ltd today announced the Australian launch of Jext, a new adrenaline autoinjector now listed on the Pharmaceutical Benefits Scheme (PBS) and available nationally, supporting subsidised access for eligible patients for the emergency treatment of anaphylaxis (1-2).    The introduction of Jext adds an additional PBS listed adrenaline autoinjector option to the established anaphylaxis treatment landscape in Australia, providing healthcare professionals and pharmacists with greater...

VAXCHORA® is indicated for active immunisation against disease caused by Vibrio cholerae serogroup O1 in adults and children aged 2 years...

As of February 17 2023, Biocelect Pty Ltd is proud to have added IMOJEV (Japanese encephalitis vaccine, live attenuated) to our portfolio...